Sex as a Critical Variable in Basic and Pre-Clinical Studies of Fibrodysplasia Ossificans Progressiva
Biomolecules · 2024
DOI: 10.3390/biom14020177 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Lorraine N Burdick und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular & Cell Biology, University of Connecticut Stem Cell Institute, University of Connecticut, Storrs, CT 06269, USA. Hauptthemen laut MEDLINE: Myositis Ossificans, Ossification, Heterotopic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIAMS, between Alexion Pharmaceuticals and the University of Connecticut.
Abstract (Originalsprache)
Heterotopic ossification (HO) is most dramatically manifested in the rare and severely debilitating disease, fibrodysplasia ossificans progressiva (FOP), in which heterotopic bone progressively accumulates in skeletal muscles and associated soft tissues. The great majority of FOP cases are caused by a single amino acid substitution in the type 1 bone morphogenetic protein (BMP) receptor ACVR1, a mutation that imparts responsiveness to activin A. Although it is well-established that biological sex is a critical variable in a range of physiological and disease processes, the impact of sex on HO in animal models of FOP has not been explored. We show that female FOP mice exhibit both significantly greater and more variable HO responses after muscle injury. Additionally, the incidence of spontaneous HO was significantly greater in female mice. This sex dimorphism is not dependent on gonadally derived sex hormones, and reciprocal cell transplantations indicate that apparent differences in osteogenic activity are intrinsic to the sex of the transplanted cells. By circumventing the absolute requirement for activin A using an agonist of mutant ACVR1, we show that the female-specific response to muscle injury or BMP2 implantation is dependent on activin A. These data identify sex as a critical variable in basic and pre-clinical studies of FOP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular & Cell Biology, University of Connecticut Stem Cell Institute, University of Connecticut, Storrs, CT 06269, USA.
- Alexion Pharmaceuticals Inc., 100 College Street, New Haven, CT 06510, USA.
ORCID-Profile: Brenden B Griffith, David J Goldhamer
Förderung
- NIAMS NIH HHS
- NIAMS
- between Alexion Pharmaceuticals and the University of Connecticut
Zitieren
APA
Burdick, L. N., DelVichio, A. H., Hanson, L. R., Griffith, B. B., Bouchard, K. R., Hunter, J. W., & Goldhamer, D. J. (2024). Sex as a Critical Variable in Basic and Pre-Clinical Studies of Fibrodysplasia Ossificans Progressiva. Biomolecules. https://doi.org/10.3390/biom14020177
Vancouver
Burdick LN, DelVichio AH, Hanson LR, Griffith BB, Bouchard KR, Hunter JW, et al. Sex as a Critical Variable in Basic and Pre-Clinical Studies of Fibrodysplasia Ossificans Progressiva. Biomolecules. 2024. doi:10.3390/biom14020177
BibTeX
@article{Burdick2024,
author = {Burdick, Lorraine N and DelVichio, Amanda H and Hanson, L Russell and Griffith, Brenden B and Bouchard, Keith R and Hunter, Jeffrey W and Goldhamer, David J},
title = {Sex as a Critical Variable in Basic and Pre-Clinical Studies of Fibrodysplasia Ossificans Progressiva},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14020177}
}
EUVIMED